China’s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South Korea’s HK inno.N Corporation (KOSDAQ: 195940) for the development and commercialization of ecnoglutide injection (XW003), a novel glucagon-like peptide-1 (GLP-1) analog, for the treatment of type 2 diabetes, obesity, and metabolic associated severe hyperglycemia (MASH) in South Korea.
Per the agreement’s terms, Sciwind Biosciences is set to receive an upfront payment and is eligible for additional development, regulatory, and commercial milestones of up to USD 56 million, plus double-digit royalties on future product sales. HK inno.N Corporation secures exclusive rights to develop and market ecnoglutide in South Korea, while Sciwind retains global rights for development and commercialization outside of South Korea.
GLP-1 analogs are recognized as effective treatments for managing type 2 diabetes and obesity and show clinical potential for treating MASH. Ecnoglutide (XW003) is a novel, long-acting GLP-1 analog designed for improved biological activity, cost-effective production, and once-weekly dosing. It has shown benefits in treating patients with type 2 diabetes and obesity and has been found safe and well-tolerated in clinical trials.
HK inno.N Corporation, initially the pharmaceutical division of CJ Cheil Jedang Corp., founded in 1984, was later acquired by Kolmar Korea Corp. in 2018. The company rebranded to HK inno.N Corp. in 2020, focusing on marketing prescription drugs, health foods, and cosmetics.- Flcube.com
